<DOC>
	<DOCNO>NCT00712933</DOCNO>
	<brief_summary>This long-term continuation study provide continue treatment subject SLE .</brief_summary>
	<brief_title>A Continuation Trial Subjects With Lupus That Completed Protocol HGS1006-C1056 HGS1006-C1057</brief_title>
	<detailed_description>This trial long-term continuation study provide continue treatment subject System Lupus Erythematosus ( SLE ) .</detailed_description>
	<mesh_term>Lupus Erythematosus , Systemic</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Belimumab</mesh_term>
	<criteria>Have complete HGS 1006C1056 HGS 1006C1057 protocol Week 72 Week 48 visit , respectively . Have develop medical disease condition make patient unsuitable study opinion physician .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>SLE</keyword>
	<keyword>Belimumab</keyword>
	<keyword>Antibodies</keyword>
	<keyword>Systemic Lupus Erythematosus</keyword>
	<keyword>Lupus</keyword>
	<keyword>Autoimmune Diseases</keyword>
</DOC>